Commentary on the role of treatment-related HIV compensatory mutations on increasing virulence: new discoveries twenty years since the clinical testing of protease inhibitors to block HIV-1 replication
© Arts; licensee BioMed Central Ltd. 2012
Received: 11 September 2012
Accepted: 3 October 2012
Published: 3 October 2012
Approximately 20 years has passed since the first human trial with HIV-1 protease inhibitors. Protease inhibitors set the stage for combination therapy in the mid-1990s but are now rarely used in first-line combination therapy and reserved for salvage therapy. Initially, resistance to protease inhibitors was deemed unlikely due to the small enzymatic target with limited genetic diversity, the extended drug binding site in protease, and the need to cleave multiple sites in the HIV-1 precursor proteins. However, a highly protease inhibitor-resistant virus can emerge during treatment and is found to harbor a collection of primary drug-resistant mutations near the drug and/or substrate binding site as well as secondary mutations that compensate for fitness loss. For years, the research field has debated the impact of these secondary mutations on the emergence rates of high-level protease inhibitor resistance. A recent study poses a more pertinent question, related to disease progression in patients newly infected with a virus harboring secondary protease inhibitor-associated polymorphisms. The authors of that study show that increased rates of disease progression, inferred by increased viral loads and decreased CD4 cell counts, correlate with a fitness score of the infecting virus. The modeled fitness scores increased with an accumulation of these secondary protease inhibitors mutations, and not because of any one specific polymorphism.
KeywordsAntiretroviral drugs drug resistance CD4 cell counts fitness human immunodeficiency virus protease inhibitors viral load virulence
In 1992, I attended a Gordon Conference entitled the 'Chemotherapy of AIDS' in Oxnard, California. My notes on this conference, the program, and the collection of abstracts are buried in some dark and scary corner in my office. Fortunately, this meeting has been etched in my memory for the past 20 years, and not just for the good food and inebriating beverages. Nucleoside RT inhibitors (NRTIs) like zidovudine, didanosine, and even zalcitabine (also known as ddC for those who forgot) were still being tested in various dual combination therapies with three to six months of sustained virus control [1, 2]. Resistance was rampant with even dual NRTI therapy and yet, most pharmaceutical companies still held out a glimmer of hope that their next antiretroviral drug would work in monotherapy. At this meeting, all the pharma giants rolled out presentations on their protease inhibitors (PIs) that were being tested in phase I or II clinical trials. I remember a gaggle of chemists in the room begging presenters to keep their slides up so they could quickly scratch down the various modifications on these peptidomimetic inhibitors. Some of these PIs maintained 10-fold drops! in HIV-1 levels for up to six months without the emergence of resistance [3, 4]. At the time, the other new drugs on the block, lamivudine and nevirapine, were deemed colossal failures because viral load rebounded with a resistant HIV-1 variant almost immediately with monotherapy [5, 6]. Oh, how times have changed. A triple drug combination therapy, based on a non-NRTI (NNRTI)backbone, is now the norm for first-line therapy and anything less than complete virus suppression is deemed a treatment failure (reviewed in ).
How do these mutations emerge under PI selection? Most primary PI-resistance mutations may pre-exist at low frequency in the intrapatient HIV-1 population but their dominance with PI treatment or selection comes with a significant fitness cost . Subsequent emergence of secondary mutations is thought to compensate or dampen this fitness loss . An alternative hypothesis suggests that these 'secondary' mutations actually emerge first under drug selection to compensate and provide a framework for the emergence of primary drug-resistance mutations . Regardless, the pathway to PI resistance under PI treatment is extremely complex and likely affected by both the baseline protease sequence of the HIV-1 population and additional selective pressures, for example, overlapping cytotoxic T cell epitopes and maintaining recognition of eight cleavage sites. As described in Figure 1B and based on the Los Alamos HIV-1 sequence database, we now know that most of the 99 amino acid sites are tolerant to some sequence change in the presence or absence of PI treatment.
Initially, compensatory mutations were poorly distinguished from primary mutations conferring PI resistance. A plethora of research articles identified PI treatment-associated 'mutations' in treatment-naïve populations, especially in those infected with non-subtype B HIV-1 . Thus, the impact of these secondary mutations (which could also be wild-type sequence for some HIV-1 subtypes) on treatment outcome and emergence of PI resistance was immediately brought into question and still without resolution to date. However, a more important role for these secondary mutations may relate to replicative fitness and the ability to compensate for the fitness loss associated with primary PI-resistance mutations. In absence of the primary PI-resistance mutations, these secondary mutations or polymorphism may actually increase fitness and, as a consequence, virulence. This must be qualified with a big IF because the hypothesis assumes that replicative fitness is a direct and possibly dominant correlate of disease progression. I have spent the last 15 years of my research career providing evidence to support this virulence hypothesis [12, 13] so the excellent article by Theys et al.  serves my ego well.
The outcome of disease following transmission of HIV-1 with primary drug-resistant mutations is still a subject of great debate. In the study by Theys et al. , lower fitness scores derived from primary drug-resistance mutations did not correlate with higher CD4 cell counts or lower viral loads in treatment-naïve patients. The fitness cost of deleterious, escape mutations within a virus appears highly dependent on the time of selection pressure, relative appearance of the escape, and the rate of subsequent diversifying evolution that can lead to compensatory mutations. As we observed with emergence of cytotoxic T lymphocyte-escape mutations , compensation mutations rapidly emerge in HIV with a resumption of high virus turnover and with the intrinsically high mutation rates. Thus, some transmitted HIV-1 with primary drug resistance may be more fit than others and may not impact normal disease progression (in the absence of treatment). Likewise, reversion of the primary drug-resistance mutations in a background with compensatory mutations may result in HIV-1 that is actually more fit than the majority of wild-type virus: the central thesis of Theys et al.  If this fitness is related to virulence, infection with HIV-1 harboring PI-associated compensatory mutations may actually lead to faster disease progression as described (Figure 2) . The disconcerting aspect of this hypothesis is the probable maintenance of this virulent HIV-1 throughout disease whereas deleterious mutations in a defective HIV are more likely to revert after transmission. There is, however, a fundamental concern that questions the foundation of the Theys et al. model. Why are these compensatory polymorphisms not found at even higher frequencies in the treatment-naïve HIV-1 population if they increase fitness? It is possible that the presence of compensatory mutations requires a specific evolutionary pathway through the fitness landscape. Alone, each of these polymorphisms may result in a slight fitness cost but in order to survive, the virus must amass these small 'fitness hits' to form a genotype that might compensate for the high fitness cost of the primary drug-resistant mutation. In this example, appearance of this virus with higher virulence is unlikely without the PI selective pressure directing the evolutionary pathway.
Theys et al.  may have provided the first in vivo evidence that some HIV-1 mutants selected under drug pressure may actually be of higher replicative fitness, which in turn could lead to higher viral loads and lower CD4 cell counts. Furthermore, it is naturally assumed that all evolutionary pathways leading to drug resistance come with a fitness cost, but this is not the case. The fitness cost of NNRTI resistance is minimal at most  and multiple HIV-1 lineages evolved with intrinsic NNRTI resistance, such that mutation(s) to drug-sensitive strains actually results in reduced replicative fitness . In addition, several HIV-1 isolates resistant to entry inhibitors, such as C-C chemokine receptor type 5 antagonist, actually have higher replicative fitness than the parental wild-type strains . Collectively, these observations emphasize the need for an immediate switch in treatment regimens upon the identification of drug resistance to avoid the emergence of compensatory mutations.
Dr Eric J Arts is a Professor of Medicine in the Division of Infectious Diseases and HIV Medicine at Case Western Reserve University (CWRU) in Cleveland, Ohio. He also serves as Director of the CWRU Center for AIDS Research Laboratories in Kampala, Uganda. His research focusses primarily on HIV-1 evolution, pathogenesis and drug resistance.
human immunodeficiency virus type 1
non-nucleoside reverse transcriptase inhibitors
nucleoside reverse transcriptase inhibitors
Support for the studies on HIV-1 fitness and drug resistance has been provided by National Institutes of Health National Institute of Allergy and Infectious Disease support, AI49170. I would like to thank Drs Theys and Vandamme, Katholieke Universiteit Leuven for providing Figure 2.
- Brun-Vezinet F, Boucher C, Loveday C, Descamps D, Fauveau V, Izopet J, Jeffries D, Kaye S, Krzyanowski C, Nunn A, Schuurman R, Seigneurin JM, Tamalet C, Tedder R, Weber J, Weverling GJ: HIV-1 viral load, phenotype, and resistance in a subset of drug-naive participants from the Delta trial. The National Virology Groups. Delta Virology Working Group and Coordinating Committee. Lancet. 1997, 350: 983-990. 10.1016/S0140-6736(97)03380-1.View ArticlePubMed
- Hammer SM, Katzenstein DA, Hughes MD, Gundacker H, Schooley RT, Haubrich RH, Henry WK, Lederman MM, Phair JP, Niu M, Hirsch MS, Merigan TC: A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter. AIDS Clinical Trials Group Study 175 Study Team. N Engl J Med. 1996, 335: 1081-1090. 10.1056/NEJM199610103351501.View ArticlePubMed
- Markowitz M, Saag M, Powderly WG, Hurley AM, Hsu A, Valdes JM, Henry D, Sattler F, La MA, Leonard JM, Ho D: A preliminary study of ritonavir, an inhibitor of HIV-1 protease, to treat HIV-1 infection. N Engl J Med. 1995, 333: 1534-1539.View ArticlePubMed
- Danner SA, Carr A, Leonard JM, Lehman LM, Gudiol F, Gonzales J, Raventos A, Rubio R, Bouza E, Pintado V, Aguado AG, de Lomas JG, Delgado R, Borleffs JCC, Hsu A, Valdes JM, Boucher CAB, Cooper DA: A short-term study of the safety, pharmacokinetics, and efficacy of ritonavir, an inhibitor of HIV-1 protease. European-Australian Collaborative Ritonavir Study Group. N Engl J Med. 1995, 333: 1528-1533. 10.1056/NEJM199512073332303.View ArticlePubMed
- Wainberg MA, Salomon H, Gu Z, Montaner JS, Cooley TP, McCaffrey R, Ruedy J, Hirst HM, Cammack N, Cameron J, Nicholson W: Development of HIV-1 resistance to (-)2'-deoxy-3'-thiacytidine in patients with AIDS or advanced AIDS-related complex. AIDS. 1995, 9: 351-357.View ArticlePubMed
- Richman DD, Havlir D, Corbeil J, Looney D, Ignacio C, Spector SA, Sullivan J, Cheeseman S, Barringer K, Pauletti D: Nevirapine resistance mutations of human immunodeficiency virus type 1 selected during therapy. J Virol. 1994, 68: 1660-1666.PubMed CentralPubMed
- Arts EJ, Hazuda DJ: HIV-1 antiretroviral drug therapy. Cold Spring Harb Perspect Med. 2012, 2: a007161.PubMed CentralView ArticlePubMed
- Theys K, Deforche K, Vercauteren J, Libin P, van de Vijver DAMC, Albert J, Asjo B, Balotta C, Bruckova M, Camacho RJ, Clotet B, Coughlan S, Grossman Z, Hamouda O, Horban A, Korn K, Kostrikis LG, Kucherer C, Nielsen C, Paraskevis D, Poljak M, Puchhammer-Stockl E, Riva C, Ruiz L, Liitsola K, Schmit J, Schuurman R, Sonnerborg A, Stanekova D, Stanojevic M, et al: Treatment-associated polymorphisms in protease are significantly associated with higher viral load and lower CD4 count in newly diagnosed drug-naive HIV-1 infected patients. Retrovirology. 2012, 9: 81-10.1186/1742-4690-9-81.PubMed CentralView ArticlePubMed
- Croteau G, Doyon L, Thibeault D, McKercher G, Pilote L, Lamarre D: Impaired fitness of human immunodeficiency virus type 1 variants with high-level resistance to protease inhibitors. J Virol. 1997, 71: 1089-1096.PubMed CentralPubMed
- Nijhuis M, Schuurman R, de Jong D, Erickson J, Gustchina E, Albert J, Schipper P, Gulnik S, Boucher CA: Increased fitness of drug resistant HIV-1 protease as a result of acquisition of compensatory mutations during suboptimal therapy. AIDS. 1999, 13: 2349-2359. 10.1097/00002030-199912030-00006.View ArticlePubMed
- Weber J, Rangel HR, Chakraborty B, Marotta ML, Valdez H, Fransen K, Florence E, Connick E, Smith KY, Colebunders RL, Landay A, Kuritzkes DR, Lederman MM, Vanham G, Quinones-Mateu ME: Role of Baseline pol Genotype in HIV-1 Fitness Evolution. J Acquir Immune Defic Syndr. 2003, 33: 448-460. 10.1097/00126334-200308010-00005.View ArticlePubMed
- Arien KK, Vanham G, Arts EJ: Is HIV-1 evolving to a less virulent form in humans?. Nat Rev Microbiol. 2007, 5: 141-151. 10.1038/nrmicro1594.View ArticlePubMed
- Tebit DM, Arts EJ: Tracking a century of global expansion and evolution of HIV to drive understanding and to combat disease. Lancet Infect Dis. 2011, 11: 45-56. 10.1016/S1473-3099(10)70186-9.View ArticlePubMed
- Deforche K, Camacho R, Van LK, Lemey P, Rambaut A, Moreau Y, Vandamme AM: Estimation of an in vivo fitness landscape experienced by HIV-1 under drug selective pressure useful for prediction of drug resistance evolution during treatment. Bioinformatics. 2008, 24: 34-41. 10.1093/bioinformatics/btm540.View ArticlePubMed
- Troyer RM, McNevin J, Liu Y, Zhang SC, Krizan RW, Abraha A, Tebit DM, Zhao H, Avila S, Lobritz MA, McElrath MJ, Le GS, Mullins JI, Arts EJ: Variable fitness impact of HIV-1 escape mutations to cytotoxic T lymphocyte (CTL) response. PLoS Pathog. 2009, 5: e1000365-10.1371/journal.ppat.1000365.PubMed CentralView ArticlePubMed
- Iglesias-Ussel MD, Casado C, Yuste E, Olivares I, Lopez-Galindez C: In vitro analysis of human immunodeficiency virus type 1 resistance to nevirapine and fitness determination of resistant variants. J Gen Virol. 2002, 83: 93-101.View ArticlePubMed
- Tebit DM, Lobritz M, Lalonde M, Immonen T, Singh K, Sarafianos S, Herchenroder O, Krausslich HG, Arts EJ: Divergent evolution in reverse transcriptase (RT) of HIV-1 group O and M lineages: impact on structure, fitness, and sensitivity to nonnucleoside RT inhibitors. J Virol. 2010, 84: 9817-9830. 10.1128/JVI.00991-10.PubMed CentralView ArticlePubMed
- Anastassopoulou CG, Marozsan AJ, Matet A, Snyder AD, Arts EJ, Kuhmann SE, Moore JP: Escape of HIV-1 from a small molecule CCR5 inhibitor is not associated with a fitness loss. PLoS Pathog. 2007, 3: e79-10.1371/journal.ppat.0030079.PubMed CentralView ArticlePubMed
- The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1741-7015/10/114/prepub
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.